[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100338610":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":36,"locations":37,"responsibleParty":70,"collaborators":36,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":36,"eligibilityCriteria":78,"healthyVolunteers":79,"sex":80,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":36,"studyType":86,"phases":87,"briefSummary":89,"conditions":90,"keywords":93,"overallStatus":95,"whyStopped":36,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"Zealand Pharma","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Dasiglucagon","EXPERIMENTAL","single fixed dose (subcutaneous injection) of dasiglucagon",[13],"Drug: Dasiglucagon",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","single fixed dose (subcutaneous injection) of placebo",[19],"Drug: Placebo",[21,27],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Glucagon analogue",[9],[26],"ZP4207",{"type":22,"name":15,"description":28,"armGroupLabels":29,"otherNames":30},"Placebo for dasiglucagon",[15],[28],[32],{"name":33,"affiliation":34,"role":35},"Christina M Sylvest, MSc Pharm","Zealand Pharma A\u002FS","STUDY_DIRECTOR",null,[38,51,60],{"facility":39,"status":36,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":36},"ProSciento, Inc.","Chula Vista","California","91911","United States","US",{"type":46,"coordinates":47},"Point",[48,49],-117.0842,32.64005,{"lat":49,"lon":48},{"facility":52,"status":36,"city":53,"state":41,"zip":54,"country":43,"countryCode":44,"cosmosGeoPoint":55,"geoPoint":59,"contacts":36},"AMCR Institute","Escondido","92025",{"type":46,"coordinates":56},[57,58],-117.08642,33.11921,{"lat":58,"lon":57},{"facility":61,"status":36,"city":62,"state":63,"zip":64,"country":43,"countryCode":44,"cosmosGeoPoint":65,"geoPoint":69,"contacts":36},"Rainier Clinical Research, Inc.","Renton","Washington","98057",{"type":46,"coordinates":66},[67,68],-122.21707,47.48288,{"lat":68,"lon":67},{"type":71,"investigatorFullName":36,"investigatorTitle":36,"investigatorAffiliation":36,"oldNameTitle":36,"oldOrganization":36},"SPONSOR","100338610","phase-3-trial-to-confirm-the-clinical-efficacy-and-safety-of-dasiglucagon-in-the-treatment-of-hypoglycemia-in-subjects-with-t1dm-100338610",true,"NCT03688711","Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Subjects With T1DM","A Randomized, Double-blind, Parallel-group Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Rescue Treatment of Hypoglycemia in Subjects With Type 1 Diabetes Mellitus (T1DM) Compared to Placebo","Inclusion Criteria:\n\n* Female or male subjects with T1DM for at least 1 year; diagnostic criteria as defined by the American Diabetes Association (3).\n* Treated with insulin for T1DM for at least 1 year and with stable insulin treatment (defined as no more than a 10-unit daily variation in total daily insulin dose) 30 days prior to screening\n* Hemoglobin A1c \\\u003C10%.\n* Aged between 18 and 75 years, both inclusive.\n\nExclusion Criteria:\n\n* Previous participation in a clinical trial within the dasiglucagon in the rescue treatment of hypoglycemia program.\n* Known or suspected allergy to trial drug(s) or related products.\n* History of anaphylaxis or symptoms of severe systemic allergy (such as angioedema).\n* Previous participation in this trial. Participation being defined by signing the informed consent document.",false,"ALL","18 Years","75 Years",{"count":84,"type":85},45,"ACTUAL","INTERVENTIONAL",[88],"PHASE3","A randomized, double-blind, parallel-group trial to confirm the clinical efficacy and safety of dasiglucagon in the rescue treatment of hypoglycemia in subjects with type 1 diabetes mellitus (T1DM) compared to placebo",[91,92],"Hypoglycemia","Diabetes Mellitus, Type 1",[94],"glucagon","COMPLETED","2021-04-28",{"date":98,"type":85},"2021-05-19",{"date":100,"type":85},"2018-11-01",{"date":102,"type":85},"2019-03-11",{"name":5,"class":6},3]